The impact of early reperfusion therapy using novel pharmacological agents and advanced imaging techniques on mortality and functional outcomes in acute myocardial infarction

Acute myocardial infarction (AMI) is a leading cause of morbidity and mortality globally, driven by the blockage of blood flow to the heart muscle. Timely reperfusion therapy, which aims to restore blood flow, is essential for minimizing tissue damage and improving outcomes. This review examines the impact of early reperfusion therapy utilizing novel pharmacological agents and advanced imaging techniques on mortality and functional outcomes in AMI. Recent advances in pharmacology, including the development of fibrin-specific thrombolytics and new-generation P2Y12 inhibitors, have enhanced the efficacy of reperfusion therapy by reducing the risk of recurrent ischemic events and improving survival rates. Concurrently, advanced imaging techniques, such as cardiac magnetic resonance imaging (MRI) and positron emission tomography (PET), have improved the precision of diagnosis, guiding therapeutic decisions, and evaluating the success of interventions. However, the phenomenon of reperfusion injury remains a significant challenge, with ongoing research exploring pharmacological strategies to mitigate this issue. The integration of these innovative approaches represents a significant advancement in AMI management, offering the potential to improve both immediate and long-term patient outcomes. Further research is needed to refine these therapies and optimize their clinical application.